Blueprint Medicines (BPMC) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Blueprint Medicines (BPMC) PT Raised to $52 at Jefferies
May 4, 2017 8:24 AM EDTJefferies raised its price target on Blueprint Medicines (NASDAQ: BPMC) to $52.00 (from $42.00) while maintaining a Buy rating.
"With add'l clinical data for 2 lead candidates (BLU-285, BLU-554) in 2017 likely to strengthen their therapeutic potential, and added clarity around approval path for... More
